<DOC>
	<DOCNO>NCT02132000</DOCNO>
	<brief_summary>In premenopausal woman , endocrine adjuvant therapy breast cancer primarily consist tamoxifen alone ovarian suppressive strategy . Toremifene chlorinate derivative tamoxifen , superior risk-benefit profile . In trial , seek compare efficacy tolerability toremifene tamoxifen therapy premenopausal patient operable , estrogen and/or progesterone receptor positive breast cancer patient .</brief_summary>
	<brief_title>Efficacy Tolerability Toremifene Tamoxifen Therapy Premenopausal Estrogen Progesterone Receptor Positive Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Clinical diagnosis Breast cancer Received standard treatment ( chemotherapy , operation , radiotherapy ) premenopausal estrogen and/or progesterone receptor positive Metastatic tumor During pregnancy lactation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>